Anti-BCMA CAR T-cells for MM: durable clinical responses with ide-cel (formerly bb2121)
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2018-01-08
Просмотров: 177
Описание: CAR T-cell therapies have exhibited strong and durable responses in several hematological malignancies thus far. Now idecabtagene vicleucel (ide-cel; formerly bb2121), an anti-BCMA CAR T-cell product, is demonstrating impressive responses in relapsed/refractory multiple myeloma (MM). In this interview, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses the latest results of the ongoing CRB-401 trial (NCT02658929) of ide-cel for MM. Dr Lin covers the promising progress, response rates, response durability, MRD status and safety data from the trial so far. She also highlights the long-term follow-up and FDA breakthrough treatment designation of the product. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
